一品紅(300723.SZ):擬以500萬美元參股超長效緩釋藥製劑創新藥企業Lyndra
格隆匯6月7日丨一品紅(300723.SZ)公佈,公司於2021年6月7日召開了第二屆董事會第三十四次會議,審議通過了《關於美國子公司對外投資的議案》,同意子公司Yipinhong Pharmaceutical (USA) Limited (“Yipinhong Pharmaceutical”)擬以自有資金500萬美元(摺合人民幣約3200萬元)對Lyndra Therapeutics,Inc (“Lyndra”)進行增資。增資完成後,Lyndra將成為公司的間接參股子公司。根據公司章程,該議案無需公司股東大會審議。
Lyndra是一家生物製藥公司,致力於研發針對各類疾病的超長效口服藥物。該藥採用傳統的口服膠囊形式,但特別之處在於,患者不需要每日服用,而是按每週或每月的劑量一次性給藥。藥物一旦進入胃內,就會持續且穩定地產生療效,直到膠囊內藥物耗盡,通過胃腸道排出體外。這種超長效口服藥能夠大大地減少藥物副作用,改善藥物依從性,降低醫療成本。通過與其合作,將加快公司在創新藥板塊的業務佈局,提高公司在創新藥領域的核心競爭力。
Lyndra旨在通過開發口服的超長效緩釋口服制劑,從根本上改變患者服藥方式,減少服藥頻率增加服藥依從性,來大幅改善治療預後。通過與其合作,將加快公司在創新藥板塊的業務佈局,提高公司在創新藥領域的核心競爭力。
公司子公司通過參股全球領先的超長效緩釋藥製劑創新藥企業Lyndra,有利於增強公司在創新藥領域的核心競爭力,擴寬公司業務範圍,提高企業可持續發展能力,符合公司長遠規劃。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.